Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level
NCT ID: NCT02455934
Last Updated: 2016-02-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2015-04-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Sucrose 50 g
2. Sucrose 50 g + D-allulose (psicose) 2.5 g
3. Sucrose 50 g + D-allulose (psicose) 5 g
4. Sucrose 50 g + D-allulose (psicose) 7.5 g
5. Sucrose 50 g + D-allulose (psicose) 10 g
Primary endpoints:
1. To investigate the dose-response effects of D- allulose (psicose) with sucrose beverage on glucose tolerance
2. To investigate the dose-response effects of D- allulose (psicose) with sucrose beverage on insulin levels
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of D-allulose in Addition to Oral Sucrose Load
NCT02714413
Efficacy of D-allulose on Weight and Fat Loss and Insulin Resistance in Non-diabetic Obese Subjects
NCT02988999
The Dose Effects of Isomaltulose and Sucrose on Glycaemic and Insulinemic Response
NCT04653207
The Acute Effect of D-allulose Consumption on Postprandial Glycaemia
NCT06330636
Acute Metabolic and Endocrine Responses of Glucose and Fructose in Healthy Young Subjects
NCT02590913
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. To investigate the dose-response effects of D-allulose (psicose) with sucrose beverage on glucose tolerance
2. To investigate the dose-response effects of D-allulose (psicose) with sucrose beverage on insulin levels
Subjects and methods Study product A. Sucrose 50 g B. Sucrose 50 g + D-allulose (psicose) 2.5 g C. Sucrose 50 g + D-allulose (psicose) 5 g D. Sucrose 50 g + D-allulose (psicose) 7.5 g E. Sucrose 50 g + D-allulose (psicose) 10 g
Study plan Screening (visit 0)
* Obtain inform consent
* History taking for medical problems, smoking, alcoholic drinking, concurrent medication, contraception or menopausal status, weight history
* Measure body weight, height and calculated BMI
* Measure waist and hip circumference
* Body composition measurement by bioelectrical impedance analysis (BIA)
* Complete physical examination
* Urine pregnancy test in all female of childbearing potential
* Provide 24-hour food record
* Ask to come back within 1 week
Visit 1: (day 7 or 6-11 days)
* Complete physical examination
* Randomize subject to receive any 1 of 5 study products
* Perform OSTT with that product
* Return food record
* Provide 24-hour food record
* Adverse events evaluation
* Ask to come back within 7 +/- 4 days
Visit 2: (day 7 or 6-11 days from visit 1)
* Complete physical examination
* Randomize subject to receive any 1 of 4 study product which are left
* Perform OSTT with that product
* Return food record
* Provide 24-hour food record
* Adverse events evaluation
* Ask to come back within 7 +/- 4 days
Visit 3 (day 7 or 6-11 days from visit 2)
* Complete physical examination
* Randomize subject to receive any 1 of 3 study product which are left
* Perform OSTT with that product
* Return food record
* Provide 24-hour food record
* Adverse events evaluation
* Ask to come back within 7 +/- 4 days
Visit 4 (day 7 or 6-11 days from visit 3)
* Complete physical examination
* Randomize subject to receive any 1 of 2 study product which are left
* Perform OSTT with that product
* Return food record
* Provide 24-hour food record
* Adverse events evaluation
* Ask to come back within 7 +/- 4 days
Visit 5 (day 7 or 6-11 days from visit 4)
* Complete physical examination
* Perform OSTT with the product that is left
* Return food record
* Adverse events evaluation
Adverse Event Assessment At each visit, participants will be asked an open question as if he/she has experienced any abnormal symptoms. Any symptom reported by the participants will be recorded as an adverse events with details of the event, its severity, start and stop dates, and relationship to study products. Gastrointestinal symptoms (heartburn, distension, nausea, vomiting, abdominal pain, flatulence, constipation and diarrhea) within 24 hours after OSTT will be asked and recorded as well.
Withdrawal criteria
1. Those who are not able to complete 5 visits of OSTT within 8 weeks
2. Those who cannot provide 24-hour dietary record at each visit
3. Those who start any medication that might cause increasing in plasma glucose during participating in the study
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sucrose
Sucrose 50 g
D-allulose
Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
SAlloulose2.5
Sucrose 50 g + D-allulose (psicose) 2.5 g
D-allulose
Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
SAllulose5
Sucrose 50 g + D-allulose (psicose) 5 g
D-allulose
Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
SAllulose7.5
Sucrose 50 g + D-allulose (psicose) 7.5 g
D-allulose
Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
SAllulose10
Sucrose 50 g + D-allulose (psicose) 10 g
D-allulose
Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-allulose
Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or \>5 days and \<12 days apart.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. If female, the participant is either post-menopausal or surgically sterilized, or has a negative urine kit pregnancy test within 7 days prior to enrollment and will use adequate contraception during the study.
3. The participant has provided written informed consent prior to admission to the study.
4. Participant is able to join the entire study with 8 weeks.
5. Participant is able to keep 24-hour dietary record a day prior to each visit.
Exclusion Criteria
2. Diagnosed with diabetes mellitus
3. Those who take any medication that might be able to increase plasma glucose 1 month prior to the study or during in the study
4. Acute illness within 1 weeks prior to the study
5. Has gastrointestinal symptoms such as nausea, vomiting, loss of appetite, premature satiety, diarrhea, or chronic constipation
6. Immunocompromised status, including a debilitated state or malignancy
7. Active liver, renal, thyroid diseases
8. Lack of ability or willingness to give informed consent
9. Enrolled in any other clinical study within 3 months before enrolment
10. Any people whose life style is irregular, for example, person works at night shifts.
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kagawa University
OTHER
Chiang Mai University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Supawan Buranapin
Assisstant Professor Supawan Buranapin, MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Supawan Buranapin, MD
Role: PRINCIPAL_INVESTIGATOR
Chiang Mai University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical trial Unit, Faculty of Medicine, Chiang Mai University
Muang, ChiangMai, Thailand
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cree GM, Perlin AS. O-isopropylidene derivatives of D-allulose (D-psicose) and D-erythro-hexopyranos-2,3-diulose. Can J Biochem. 1968 Aug;46(8):765-70. doi: 10.1139/o68-117. No abstract available.
Takeshita K, Suga A, Takada G, Izumori K. Mass production of D-psicose from d-fructose by a continuous bioreactor system using immobilized D-tagatose 3-epimerase. J Biosci Bioeng. 2000;90(4):453-5. doi: 10.1016/s1389-1723(01)80018-9.
Granstrom TB, Takata G, Tokuda M, Izumori K. Izumoring: a novel and complete strategy for bioproduction of rare sugars. J Biosci Bioeng. 2004;97(2):89-94. doi: 10.1016/S1389-1723(04)70173-5.
Matsuo T, Suzuki H, Hashiguchi M, Izumori K. D-psicose is a rare sugar that provides no energy to growing rats. J Nutr Sci Vitaminol (Tokyo). 2002 Feb;48(1):77-80. doi: 10.3177/jnsv.48.77.
Matsuo T, Izumori K. d-Psicose Inhibits Intestinal alpha-Glucosidase and Suppresses the Glycemic Response after Ingestion of Carbohydrates in Rats. J Clin Biochem Nutr. 2009 Sep;45(2):202-6. doi: 10.3164/jcbn.09-36. Epub 2009 Aug 28.
Iida T, Kishimoto Y, Yoshikawa Y, Hayashi N, Okuma K, Tohi M, Yagi K, Matsuo T, Izumori K. Acute D-psicose administration decreases the glycemic responses to an oral maltodextrin tolerance test in normal adults. J Nutr Sci Vitaminol (Tokyo). 2008 Dec;54(6):511-4. doi: 10.3177/jnsv.54.511.
Hayashi N, Iida T, Yamada T, Okuma K, Takehara I, Yamamoto T, Yamada K, Tokuda M. Study on the postprandial blood glucose suppression effect of D-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects. Biosci Biotechnol Biochem. 2010;74(3):510-9. doi: 10.1271/bbb.90707. Epub 2010 Mar 7.
Hossain A, Yamaguchi F, Matsunaga T, Hirata Y, Kamitori K, Dong Y, Sui L, Tsukamoto I, Ueno M, Tokuda M. Rare sugar D-psicose protects pancreas beta-islets and thus improves insulin resistance in OLETF rats. Biochem Biophys Res Commun. 2012 Sep 7;425(4):717-23. doi: 10.1016/j.bbrc.2012.07.135. Epub 2012 Aug 1.
Ochiai M, Onishi K, Yamada T, Iida T, Matsuo T. D-psicose increases energy expenditure and decreases body fat accumulation in rats fed a high-sucrose diet. Int J Food Sci Nutr. 2014 Mar;65(2):245-50. doi: 10.3109/09637486.2013.845653. Epub 2013 Oct 21.
Matsuo T, Izumori K. Effects of dietary D-psicose on diurnal variation in plasma glucose and insulin concentrations of rats. Biosci Biotechnol Biochem. 2006 Sep;70(9):2081-5. doi: 10.1271/bbb.60036. Epub 2006 Sep 7.
Ochiai M, Nakanishi Y, Yamada T, Iida T, Matsuo T. Inhibition by dietary D-psicose of body fat accumulation in adult rats fed a high-sucrose diet. Biosci Biotechnol Biochem. 2013;77(5):1123-6. doi: 10.1271/bbb.130019. Epub 2013 May 7.
Chung YM, Hyun Lee J, Youl Kim D, Hwang SH, Hong YH, Kim SB, Jin Lee S, Hye Park C. Dietary D-psicose reduced visceral fat mass in high-fat diet-induced obese rats. J Food Sci. 2012 Feb;77(2):H53-8. doi: 10.1111/j.1750-3841.2011.02571.x.
Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006 Mar;40(3):235-43. doi: 10.1097/00004836-200603000-00015.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMU-D-alloluse01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.